Skip to main
PRQR

ProQR Therapeutics (PRQR) Stock Forecast & Price Target

ProQR Therapeutics (PRQR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ProQR Therapeutics NV demonstrates a strong potential for stock appreciation due to its promising pipeline of RNA-based therapeutics, particularly if the company advances its products into clinical stages sooner than projected and achieves pivotal proof of concept data in humans. The innovative Axiomer RNA base-editing platform is anticipated to generate significant clinical data, which could enhance the company's valuation. Additionally, management's assertion that the current cash position supports operations through mid-2027 provides a solid financial foundation for executing its development plans.

Bears say

ProQR Therapeutics NV reported a significant net loss of €12.2 million for the quarter, showing a marked decline from a loss of €2.7 million in the same period of the previous year, indicating worsening financial performance. The company's future is highly contingent on the outcomes of its Phase Ib/II/III studies, which carry the risk of negatively impacting shares based on their results. Furthermore, advancements in treatment methods for genetic diseases could potentially make ProQR's therapies non-competitive or obsolete, further complicating its market position.

ProQR Therapeutics (PRQR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ProQR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ProQR Therapeutics (PRQR) Forecast

Analysts have given ProQR Therapeutics (PRQR) a Buy based on their latest research and market trends.

According to 7 analysts, ProQR Therapeutics (PRQR) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ProQR Therapeutics (PRQR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.